^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    GENE:

    CCL8 (C-C Motif Chemokine Ligand 8)

    i
    Other names: CCL8, C-C Motif Chemokine Ligand 8, MCP-2, HC14, SCYA8, Small Inducible Cytokine Subfamily A (Cys-Cys), Member 8 (Monocyte Chemotactic Protein 2), Monocyte Chemoattractant Protein 2, Chemokine (C-C Motif) Ligand 8, Monocyte Chemotactic Protein 2, Small-Inducible Cytokine A8, C-C Motif Chemokine 8, SCYA10, MCP2
    18d
    Inflammatory profile associated with hyperglycemia in children with type 1 diabetes. (PubMed, J Diabetes Complications)
    A broad range of inflammatory mediators are correlated with HbA1c in children with T1D. These inflammatory changes precede development of T1D complications, suggesting that possible pathophysiologic involvement should be investigated.
    Journal
    |
    IFNG (Interferon, gamma) • IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • CXCL8 (Chemokine (C-X-C motif) ligand 8) • IL2 (Interleukin 2) • CXCL13 (Chemokine (C-X-C motif) ligand 13) • MMP2 (Matrix metallopeptidase 2) • CCL2 (Chemokine (C-C motif) ligand 2) • IL18 (Interleukin 18) • CCL8 (C-C Motif Chemokine Ligand 8) • IL17A (Interleukin 17A) • IL23A (Interleukin 23 Subunit Alpha) • CCL27 (C-C Motif Chemokine Ligand 27) • CXCL5 (Chemokine (C-X-C motif) ligand 5) • IL13 (Interleukin 13) • IL21 (Interleukin 21) • IL4 (Interleukin 4) • MMP1 (Matrix metallopeptidase 1) • CXCL1 (Chemokine (C-X-C motif) ligand 1) • IL33 (Interleukin 33) • LIF (LIF Interleukin 6 Family Cytokine)
    19d
    Evaluation of Clinical and Prognostic Roles of CCL8 in Urinary Bladder Cancer and Upper Tract Urothelial Carcinoma. (PubMed, Appl Immunohistochem Mol Morphol)
    CCL8 has the potential to be a prognostic biomarker, aiding in patient stratification and treatment planning. Further multicenter studies with longer follow-up periods and functional validation are required to confirm these findings and fully understand the role of CCL8 in urothelial carcinoma.
    Journal
    |
    CCL8 (C-C Motif Chemokine Ligand 8)
    1m
    An immune infiltration-based risk scoring system for prognostic stratification in colorectal adenocarcinoma. (PubMed, Ecancermedicalscience)
    Multivariate Cox analysis identified tumour (T stage), node (N stage) and risk score as independent prognostic factors. Our risk scoring system based on CCL8 and TYR effectively stratifies CRC patients into distinct prognostic groups and could guide treatment decisions, particularly when integrated with TNM staging in a nomogram.
    Journal
    |
    CCL8 (C-C Motif Chemokine Ligand 8)
    1m
    IL-6 drives chemoimmunotherapy resistance in NSCLC by reprogramming myeloid cells and impairing cytotoxic lymphocyte function. (PubMed, Cancer Lett)
    Mechanistically, IL-6 drives formation of an immunosuppressive TIME by promoting protumour macrophage polarisation. This, in turn, suppress cytotoxic T cell infiltration, promoting Treg expansion, and impairing NK cell function, indicating that the targeting of IL-6 represents a promising strategy to overcome resistance to chemoimmunotherapy.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    CD8 (cluster of differentiation 8) • IL6 (Interleukin 6) • CCL8 (C-C Motif Chemokine Ligand 8) • NR4A1 (Nuclear Receptor Subfamily 4 Group A Member 1)
    1m
    Lutein reverses M2 macrophages polarization and exhibits antitumor effects on human triple-negative breast cancer cells. (PubMed, Mol Biol Rep)
    These findings suggest that lutein reprograms M2 macrophages toward an M1-like phenotype and disrupts tumor-promoting signaling within the TNBC microenvironment, highlighting its potential as an adjunct therapeutic agent.
    Journal
    |
    IFNG (Interferon, gamma) • IL6 (Interleukin 6) • BCL2L1 (BCL2-like 1) • CXCL8 (Chemokine (C-X-C motif) ligand 8) • BIRC5 (Baculoviral IAP repeat containing 5) • CCL20 (C-C Motif Chemokine Ligand 20) • IL10 (Interleukin 10) • CD14 (CD14 Molecule) • CCL2 (Chemokine (C-C motif) ligand 2) • CSF2 (Colony stimulating factor 2) • TGFB1 (Transforming Growth Factor Beta 1) • CCL8 (C-C Motif Chemokine Ligand 8) • MMP9 (Matrix metallopeptidase 9) • CCL3 (C-C Motif Chemokine Ligand 3) • IL4 (Interleukin 4) • MRC1 (Mannose Receptor C-Type 1)
    1m
    Programmed death-ligand 1 (PD-L1) Modulates Chemokine Production Via the TLR4/TRAF6 Signaling Axis During LPS + IFN-γ-Induced Endotoxemia-mimicked Sepsis. (PubMed, Inflammation)
    Through combinatorial approaches, including immunoprecipitation‒mass spectrometry (IP‒MS), molecular docking, and site-directed mutagenesis, we preliminarily elucidated that PD-L1 likely governs the chemotactic mediators CCL8 and CXCL9 via the TLR4/TRAF6 signaling axis. These findings collectively establish the previously unappreciated regulatory capacity of macrophage-intrinsic PD-L1 in chemokine modulation during sepsis, potentially informing the development of innovative therapeutic strategies targeting immune dysregulation in critical care settings.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • PD-1 (Programmed cell death 1) • IFNG (Interferon, gamma) • CXCL9 (Chemokine (C-X-C motif) ligand 9) • IL2 (Interleukin 2) • TLR4 (Toll Like Receptor 4) • CCL8 (C-C Motif Chemokine Ligand 8) • TRAF6 (TNF Receptor Associated Factor 6)
    2ms
    A Potential Link Between Preoperative Inflammation Biomarkers and Acute Postoperative Pain Following VATS. (PubMed, Clin J Pain)
    The current study is the first to demonstrate an association between preoperative inflammatory biomarkers, opioid consumption, and acute postoperative pain after VATS in patients with lung cancer. Future studies are needed to confirm these findings.
    Journal
    |
    VEGFA (Vascular endothelial growth factor A) • EIF4EBP1 (Eukaryotic translation initiation factor 4E binding protein 1) • CCL8 (C-C Motif Chemokine Ligand 8)
    2ms
    Transcriptomic profiling of a canine malignant eyelid melanoma. (PubMed, Braz J Vet Med)
    In addition, comparative analyses revealed conserved gene signatures in human basal cell carcinoma of the eyelids, emphasizing the importance of canine models in translational oncology. This comprehensive molecular characterization provides new insights into the pathogenesis of canine eyelid melanoma and identifies key biomarkers and pathways that may be relevant for future therapeutic interventions in veterinary and comparative oncology.
    Journal
    |
    CXCL8 (Chemokine (C-X-C motif) ligand 8) • CXCL10 (Chemokine (C-X-C motif) ligand 10) • CCL23 (Chemokine (C-C motif) ligand 23) • CCL8 (C-C Motif Chemokine Ligand 8) • CCL3 (C-C Motif Chemokine Ligand 3) • MIR134 (MicroRNA 134)
    3ms
    Role of CCL8 in cancer immunity and tumor progression: Implications for cancer treatment. (PubMed, Biochim Biophys Acta Rev Cancer)
    Furthermore, we underscore the potential of CCL8 as a biomarker for the progression of cancer and other diseases, and its clinical relevance in predicting therapeutic responses via targeted antagonists and receptor blockade. Finally, by integrating current insights into the role of CCL8 in tumor cell proliferation within the cancer immune microenvironment, this review aims to elucidate the biological significance of CCL8 and facilitate the development of novel diagnostic and therapeutic strategies.
    Review • Journal
    |
    CCL8 (C-C Motif Chemokine Ligand 8)
    3ms
    TREM2 facilitates gastric cancer progression and immune evasion via inhibiting TRIM21-mediated STAT1 degradation in tumor-associated macrophages. (PubMed, Cell Death Dis)
    Collectively, our findings establish TREM2+ TAMs as key drivers of GC progression and immune evasion. Targeting TREM2+ TAMs represents a promising therapeutic strategy to overcome resistance to anti-PD-L1 therapy and reshape the tumor immune microenvironment.
    Journal
    |
    SYK (Spleen tyrosine kinase) • CCL8 (C-C Motif Chemokine Ligand 8) • STAT1 (Signal Transducer And Activator Of Transcription 1) • TRIM21 (Tripartite Motif Containing 21)
    3ms
    CBX6 induces CD8+ T cell exhaustion and tumor development in esophageal squamous cell carcinoma through SMARCD1-mediated CCL8 secretion and lactate efflux. (PubMed, Cell Biol Toxicol)
    Tissue microarrays analysis suggested that CBX6 and SMARCD1 were linked to immunosuppression and poor prognosis in clinical samples. In conclusion, this study suggests that CBX6 induces CD8+ T cell exhaustion and tumor development in ESCC through SMARCD1-mediated CCL8 secretion and lactate efflux.
    Journal
    |
    CD8 (cluster of differentiation 8) • CCL8 (C-C Motif Chemokine Ligand 8) • BCL11B (BAF Chromatin Remodeling Complex Subunit BCL11B) • SLC16A3 (Solute Carrier Family 16 Member 3) • SMARCD1 (SWI/SNF Related, Matrix Associated, Actin Dependent Regulator Of Chromatin, Subfamily D, Member 1) • CBX6 (Chromobox 6)
    4ms
    Decoding Fibromyalgia: Genetic Insights into Gut and Immune System Interactions. (PubMed, J Pain Res)
    Through Gene Ontology (GO) functional enrichment and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analyses, the findings suggest their involvement in immune regulation, inflammatory responses, and viral pathways. These findings provide new insights into potential therapeutic targets for modulating gut health and immune responses, opening new avenues for future research and clinical interventions.
    Journal
    |
    TNFA (Tumor Necrosis Factor-Alpha) • LIFR (LIF Receptor Subunit Alpha) • CCL8 (C-C Motif Chemokine Ligand 8) • CXCL5 (Chemokine (C-X-C motif) ligand 5) • LIF (LIF Interleukin 6 Family Cytokine)